论文信息 - SAFETY AND IMMUNOGENICITY OF LIVE VARICELLA VIRUS VACCINE IN CHILDREN WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE 1

SAFETY AND IMMUNOGENICITY OF LIVE VARICELLA VIRUS VACCINE IN CHILDREN WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE 1

Live varicella virus vaccine was administered to 10 stable human immunodeficiency virus type 1 (HIV-1)-infected children. Subjects were monitored for adverse reactions, HIV-1 plasma levels, CD4+ T cell counts and immune responses. The vaccine was well-tolerated. Varicella-zoster virus-specific lymphocyte proliferative responses were detected in all subjects by 4 weeks and in 9 of 10 subjects 1 year after vaccination.

J. Church | S. Armenian | Jin-Young Han | T. Dunaway

[1] B. LaFleur,et al. Varicella-Zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy. , 2004, The Journal of infectious diseases.

[2] C. Chan,et al. Immunization of HIV-infected children with varicella vaccine. , 2001, The Journal of pediatrics.

[3] E. Shapiro,et al. The effectiveness of the varicella vaccine in clinical practice. , 2001, The New England journal of medicine.

[4] J. Church,et al. Failure of intravenous immunoglobulin to prevent varicella-zoster infection. , 2000, The Pediatric infectious disease journal.

[5] M. Rousseau,et al. Vaccination and HIV: a review of the literature. , 1999, Vaccine.

[6] M. Capasso,et al. Varicella and zoster in children with human immunodeficiency virus infection. , 1998, The Pediatric infectious disease journal.

[7] A. Arvin. Immune responses to varicella-zoster virus. , 1996, Infectious disease clinics of North America.

[8] J. Church,et al. Lymphocyte phenotype does not predict immune function in pediatric patients infected with human immunodeficiency virus type 1. , 1989, The Journal of pediatrics.